2023
Biomarker analysis from a phase I/I1b study of regorafenib and nivolumab (rego/nivo) in microsatellite stable (MSS) colorectal cancer (CRC).
Yu J, Kim Y, Mehta R, Miao R, Strosberg J, Imanirad I, Kim D, Kim R. Biomarker analysis from a phase I/I1b study of regorafenib and nivolumab (rego/nivo) in microsatellite stable (MSS) colorectal cancer (CRC). Journal Of Clinical Oncology 2023, 41: 188-188. DOI: 10.1200/jco.2023.41.4_suppl.188.Peer-Reviewed Original ResearchPathway enrichment analysisReceptor signaling pathwayEnrichment analysisProgressive diseaseB cell activationGene OntologyCell-substrate junction assemblySignaling pathwayGO pathway enrichment analysisPositive regulation of B cell activationDownregulated pathwaysKyoto Encyclopedia of GenesSerine-type endopeptidase activityPredictive biomarkersMSS-CRCKEGG pathway enrichment analysisRegulation of B cell activationECM-receptor interactionTumor samplesEncyclopedia of GenesColorectal cancerGenomes (KEGGExtracellular matrixPre-treatment tumor samplesGene set enrichment analysisBiomarker analysis to predict response in patients with metastatic mismatch repair proficient colorectal cancer treated with regorafenib and nivolumab.
Miao R, Kim D, Yu J, Kovari B, Mehta R, Strosberg J, Imanirad I, Iyer S, Uhlik M, Benjamin L, Kim R. Biomarker analysis to predict response in patients with metastatic mismatch repair proficient colorectal cancer treated with regorafenib and nivolumab. Journal Of Clinical Oncology 2023, 41: 228-228. DOI: 10.1200/jco.2023.41.4_suppl.228.Peer-Reviewed Original ResearchProgression free survivalMedian progression free survivalTreated with regorafenibOverall survivalPD-L1Tumor microenvironmentColorectal cancerMedian OSCD8 expressionPartial responseTreg cellsImmune desertPredictive biomarkersAssociated with prolonged progression free survivalMismatch repair-proficient colorectal cancersProlonged progression free survivalDisease control ratePhase I/Ib studyPredicting clinical benefitPD-L1 expressionPretreatment tumor samplesPotential predictive biomarkersPMMR colorectal cancerBiomarker-positiveBiomarker-negative patients
2017
Use of alternative medicine for cancer and its impact on survival.
Johnson S, Gross C, Park H, Yu J. Use of alternative medicine for cancer and its impact on survival. Journal Of Clinical Oncology 2017, 35: e18175-e18175. DOI: 10.1200/jco.2017.35.15_suppl.e18175.Peer-Reviewed Original ResearchCharlson-Deyo comorbidity scoreConventional cancer treatmentsNational Cancer DatabaseAlternative medicineColorectal cancerCancer treatmentComorbidity scoreCox proportional hazards regressionGreater riskNon-metastatic breastYear of diagnosisAlternative medicine useKaplan-Meier methodSubgroup of patientsAlternative medicine utilizationProportional hazards regressionCancer patient characteristicsDisease-related factorsLog-rank testAnti-cancer treatmentChi-square testPatterns of utilizationHigher socioeconomic statusHormone therapyOverall survival
2015
Historical trends of radiotherapy use in prevalent malignancies over 38 years in SEER
Yeboa D, Aneja S, Montana G, Roberts K, Yu J. Historical trends of radiotherapy use in prevalent malignancies over 38 years in SEER. Journal Of Radiation Oncology 2015, 4: 11-17. DOI: 10.1007/s13566-015-0182-y.Peer-Reviewed Original ResearchIntensity-modulated radiation therapyProstate cancerRadiation therapyEnd Results (SEER) databaseAmerican Joint CommitteeBreast cancer treatmentUse of RTInitial therapyMethodsThe SurveillanceRT receiptNonmetastatic patientsResults databaseCommon malignancyTherapy utilizationColorectal cancerLung cancerPrevalent malignancyCancer sitesRadiotherapy useHigh incidenceMedical treatmentJoint CommitteeDisease sitesPersistent decreaseTherapy
2013
Changes in early- and late-stage colorectal cancer incidence during the era of screening: 1976-2009.
Yang D, Gross C, Yu J. Changes in early- and late-stage colorectal cancer incidence during the era of screening: 1976-2009. Journal Of Clinical Oncology 2013, 31: 1522-1522. DOI: 10.1200/jco.2013.31.15_suppl.1522.Peer-Reviewed Original ResearchLate-stage colorectal cancerColorectal cancerCancer incidenceLate-stage colorectal cancer diagnosisEarly-stage colorectal cancerNon-screened populationColorectal cancer incidenceEnd Results (SEER) databaseColorectal cancer incidence dataAdults 50 yearsColorectal cancer diagnosisBreast cancer screeningLate-stage cancerEarly-stage cancerCancer incidence dataColorectal screeningResults databaseCancer screeningAdults 50Curable stageSubsequent diagnosisStage cancerDetects cancerNHS dataCancer
2011
Radiation oncologist density and pancreatic cancer mortality.
Aneja S, Yu J. Radiation oncologist density and pancreatic cancer mortality. Journal Of Clinical Oncology 2011, 29: 350-350. DOI: 10.1200/jco.2011.29.4_suppl.350.Peer-Reviewed Original ResearchPC mortalityPancreatic cancerRadiation oncologistsCurative treatmentCancer mortalityTreatment of PCRadiation oncologist densityPancreatic cancer mortalityEsophageal cancer mortalityHealth care facilitiesArea Resource FileMultidisciplinary careCancer RegistryColorectal cancerCancer patientsPC outcomesMultivariate regression modelCare facilitiesU.S. CentersMortalityDisease controlSignificant financial relationshipSocioeconomic statusRadiation oncologyResource File